Tumorigenesis of K-ras mutation in human endometrial carcinoma via upregulation of estrogen receptor

Gynecologic Oncology

Volumn 101, Issue 2, 2006, Pages 274-279

  Tu, Zheng ^a   Gui, Liming ^a   Wang, Jianliu ^a   Li, Xiaoping ^a   Sun, Pengming ^a   Wei, Lihui ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Endometrial carcinoma; Estrogen receptor; K ras; Signaling pathway; Tumorigenesis

Indexed keywords

ASPARTIC ACID; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; K RAS PROTEIN; MUTANT PROTEIN; THYMIDINE; TRITIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN 3T3; CELL TRANSFORMATION; COLONY FORMATION; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; EMBRYO; ENDOMETRIUM CARCINOMA; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE INSERTION; GENE MUTATION; GENE VECTOR; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INCUBATION TIME; MALIGNANT TRANSFORMATION; MOUSE; MUTATIONAL ANALYSIS; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR UPREGULATION; REPORTER GENE; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ANIMALS; CELL GROWTH PROCESSES; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, RAS; GENES, REPORTER; HUMANS; LUCIFERASES; MICE; NIH 3T3 CELLS; PLASMIDS; POINT MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; RECEPTORS, ESTROGEN; TRANS-ACTIVATION (GENETICS); TRANSFECTION; UP-REGULATION;

EID: 33646387173     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.10.016     Document Type: Article

References (30)

1. Thapar R., Williams J.G., and Campbell S.L. NMR characterization of full-length farnesylated and non-farnesylated H-Ras and its implications for Raf activation. J. Mol. Biol. 343 (2004) 1391-1408
2. Wang Y., Zhang Z., Lubet R., and You M. Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf. Oncogene 24 (2005) 3042-3049
3. Murua E.H., Gunther K., Richter A., Soller J.T., Winkler S., Nolte I., et al. Absence of ras-gene hot-spot mutations in canine fibrosarcomas and melanomas. Anticancer Res. 24 (2004) 3027-3028
4. Tanoguchi K., Yaegashi N., Jiko K., Maekawa A., Sato S., and Yajima A. K-ras point mutations in spontaneously occurring endometrial adenocarcinomas in the Donryu rat. Tohoku J. Exp. Med. 189 (1999) 87-93
5. Tsukuda K., Tanino M., Soga H., Shimizu N., and Shimizu K. A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma. Biochem. Biophys. Res. Commun. 278 (2000) 653-658
6. Vitale-Cross L., Amornphimoltham P., Fisher G., Molinolo A.A., and Gutkind J.S. Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res. 64 (2004) 8804-8807
7. Conlin A., Smith G., Carey F.A., Wolf C.R., and Steele R.J. The prognostic significance of K-ras, p53 and APC mutations in colorectal carcinoma. Gut (2005)
8. Schramm K., Krause K., Bittroff-Leben A., Goldin-Lang P., Thiel E., and Kreuser E.D. Activated K-ras is involved in regulation of integrin expression in human colon carcinoma cells. Int. J. Cancer 87 (2000) 155-164
9. Fernandez C., Chetaille B., Tasei A.M., Sastre B., Sahel J., and Payan-Defais M.J. From pancreatic intraepithelial neoplasia to cancer: a dramatic progression with K-ras status analysis. Gastroenterol. Clin. Biol. 29 (2005) 465-468
10. Kuroki T., Tajima Y., Matsuo K., and Kanematsu T. Genetic alterations in gallbladder carcinoma. Surg. Today 35 (2005) 101-105
11. Soung Y.H., Lee J.W., Kim S.Y., Seo S.H., Park W.S., Nam S.W., et al. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch. 446 (2005) 483-488
12. Hongyo T., Hoshida Y., Nakatsuka S., Syaifudin M., Kojya S., Yang W.I., et al. p53, K-ras, c-kit and beta-catenin gene mutations in sinonasal NK/T-cell lymphoma in Korea and Japan. Oncol. Rep. 13 (2005) 265-271
13. Okuda T., Otsuka J., Sekizawa A., Saito H., Makino R., Kushima M., et al. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecol. Oncol. 88 (2003) 318-325
14. Dinulescu D.M., Ince T.A., Quade B.J., Shafer S.A., Crowley D., and Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat. Med. 11 (2005) 63-70
15. Semczuk A., Skomra D., Cybulski M., and Jakowicki J.A. Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations. Histochem. J. 33 (2001) 193-200
16. Qi X., Tang J., Pramanik R., Schultz R.M., Shirasawa S., Sasazuki T., et al. p38 MAPK activation selectively induces cell death in K-ras-mutated human colon cancer cells through regulation of vitamin D receptor. J. Biol. Chem. 279 (2004) 22138-22144
17. Tang J., Qi X., Mercola D., Han J., and Chen G. Essential role of p38gamma in K-Ras transformation independent of phosphorylation. J. Biol. Chem. 280 (2005) 23910-23917
18. Maciag A., Sithanandam G., and Anderson L.M. Mutant K-rasV12 increases COX-2, peroxides and DNA damage in lung cells. Carcinogenesis 25 (2004) 2231-2237
19. Hori M., Takechi K., Arai Y., Yomo H., Itabashi M., Shimazaki J., et al. Comparison of macroscopic appearance and estrogen receptor-alpha regulators after gene alteration in human endometrial cancer. Int. J. Gynecol. Cancer 10 (2000) 469-476
20. Lax S.F., Kendall B., Tashiro H., Slebos R.J., and Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88 (2000) 814-824
21. Zhou R., Gui L., Wei L., Guo C., Fu Q., and Yu X. Relationships between the mutation of K-ras gene exon 1 and the clinical conditions of endometrial carcinoma. J. Beijing Med. Univ. 31 (1999) 348-350
22. Wallen M., Tomas E., Visakorpi T., Holli K., and Maenpaa J. Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene. Cancer Chemother. Pharmacol. 55 (2005) 343-346
23. Hachisuga T., Miyakawa T., Tsujioka H., Horiuchi S., Emoto M., and Kawarabayashi T. K-ras mutation in tamoxifen-related endometrial polyps. Cancer 98 (2003) 1890-1897
24. Fujimoto J., Sakaguchi H., Aoki I., Khatun S., Toyoki H., and Tamaya T. Steroid receptors and metastatic potential in endometrial cancers. J. Steroid Biochem. Mol. Biol. 75 (2000) 209-212
25. Harlow E.D. In: Lane D. (Ed). Using Antibodies: A Laboratory Manual (1999), Cold Spring Harbor Labour Press, Cold Spring Harbor, N.Y. 233-345
26. Rennefahrt U., Janakiraman M., Ollinger R., and Troppmair J. Stress kinase signaling in cancer: fact or fiction?. Cancer Lett. 217 (2005) 1-9
27. Lax S.F. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 444 (2004) 213-223
28. Kato K., Horiuchi S., Takahashi A., Ueoka Y., Arima T., Matsuda T., et al. Contribution of estrogen receptor alpha to oncogenic K-Ras-mediated NIH3T3 cell transformation and its implication for escape from senescence by modulating the p53 pathway. J. Biol. Chem. 277 (2002) 11217-11224
29. Ninomiya Y., Kato K., Takahashi A., Ueoka Y., Kamikihara T., Arima T., et al. K-Ras and H-Ras activation promote distinct consequences on endometrial cell survival. Cancer Res. 64 (2004) 2759-2765
30. Al Mulla F., and MacKenzie E.M. Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. J. Pathol. 195 (2001) 549-556